134 related articles for article (PubMed ID: 19812537)
1. Parathyroid hormone measurement in CKD.
Souberbielle JC; Roth H; Fouque DP
Kidney Int; 2010 Jan; 77(2):93-100. PubMed ID: 19812537
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
4. Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods.
Monge M; Jean G; Bacri JL; Lemaitre V; Masy E; Joly D; Souberbielle JC
Clin Chem Lab Med; 2009; 47(3):362-6. PubMed ID: 19199835
[TBL] [Abstract][Full Text] [Related]
5. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of serum parathyroid hormone levels in kidney transplant recipients with moderate-to-advanced CKD.
Kovesdy CP; Molnar MZ; Czira ME; Rudas A; Ujszaszi A; Sarvary E; Ambrus C; Szathmari M; Remport A; Mucsi I
Nephron Clin Pract; 2011; 118(2):c78-85. PubMed ID: 21150215
[TBL] [Abstract][Full Text] [Related]
7. Serum parathyroid hormone concentrations measured by chemiluminescence and electrochemiluminescence methods — are the results comparable in haemodialysis patients with chronic kidney disease?
Kuczera P; Maszczyk A; Machura E; Kurzak E; Adamczak M; Więcek A
Endokrynol Pol; 2015; 66(3):219-23. PubMed ID: 26136130
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold.
Metzger M; Houillier P; Gauci C; Haymann JP; Flamant M; Thervet E; Boffa JJ; Vrtovsnik F; Froissart M; Stengel B; Ureña-Torres P;
J Clin Endocrinol Metab; 2013 Jul; 98(7):2922-8. PubMed ID: 23633202
[TBL] [Abstract][Full Text] [Related]
10. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory?
Souberbielle JC; Cavalier E; Jean G
Clin Chem Lab Med; 2010 Jun; 48(6):769-74. PubMed ID: 20298134
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Elecsys PTH(1-84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients.
Tan K; Ong L; Sethi SK; Saw S
Clin Biochem; 2013 Jun; 46(9):781-6. PubMed ID: 23384535
[TBL] [Abstract][Full Text] [Related]
12. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
[TBL] [Abstract][Full Text] [Related]
15. PTH--a particularly tricky hormone: why measure it at all in kidney patients?
Garrett G; Sardiwal S; Lamb EJ; Goldsmith DJ
Clin J Am Soc Nephrol; 2013 Feb; 8(2):299-312. PubMed ID: 22403273
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone measurement in chronic kidney disease: Impact of inter-method variability on mineral bone disease assessment.
White CA; Sarabia S; Collier CP; McCudden C; Holden RM
Clin Biochem; 2021 Aug; 94():62-66. PubMed ID: 33895125
[TBL] [Abstract][Full Text] [Related]
17. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease.
Almond A; Ellis AR; Walker SW;
Ann Clin Biochem; 2012 Jan; 49(Pt 1):63-7. PubMed ID: 22096021
[TBL] [Abstract][Full Text] [Related]
18. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between glomerular filtration rate, uric acid, and parathyroid hormone in children].
Diallo D; Dubourg L; Ranchin B; Cochat P; Bacchetta J
Arch Pediatr; 2013 Jun; 20(6):601-7. PubMed ID: 23642898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
